Innatoss Laboratories Launches Neutralizing Antibody Testing Service Against SARS-CoV-2 using GenScript's cPass ™ Kit

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service of this kind for the public. "Our collaboration with GenScript is a crucial step toward offering high-quality, innovative products to combat the COVID-19 pandemic, which poses a global threat to public health," said Dr. Anja Garritsen, CEO of Innatoss.  "cPass ™ uses a novel test method that is capable of detecting the presence of virus-specific neutralizing antibodies. The test would be useful in determining the longevity of potential immunity both in individuals and the broader population, and facilitating development of vaccines and monoclonal antibody therapy development. It will become the key test to monitor titers once vaccination has been implemented." Innatoss recently performed a study in Kessel, a city in the south of the Netherlands that was severely affected during the first wave of COVID-19, to determine the longevity of binding antibodies versus neutralizing antibodies in individuals.  The people were initially tested 2-4 months post infection using a rapid test for IgG and IgM levels, and then were retested 2-3 months later.  Afterwards, the patients' samples were tested for neutralizing antibodies using the GenScript cPass™ kit.  In 90 percent of the cases the binding antibody levels dropped significantly over time while the level of functional antibodies (neutralizing antibodies) was stable in 70 percent of those tested.